PROJECT SUIVIMARY (See instmctions): This translational Program Project in lung disease is focused on advancing the field of carbon monoxide (CO) therapeutics in part by examining the impact of low dose CO in the metabolome of lipid mediators (LM), including classic eicosanoids (e.g. prostaglandins and leukotrienes) as well as actions and formation of novel specialized pro-resolving mediators (SPM). In service to achieve this Program Project's goals, this LMLipidomics and Metabolomics Core C will provide centralized, standardized and coordinated lipid mediator (LM) lipidomic profiling, specific mediators and procedures for Projects 1-4. Specifically, Core C will execute newly established procedures for SPM lipidomics and LM pathway metabolomics as a central service required routinely by Projects 1-4. This core will also provide validated eicosanoids, resolvins and related mediators to each of the individual projects as well as maintain quality for their use in each project for assessing CO and its relationship to specific LM and SPM. This Core will set-up, validate and implement new analytical methods as needed for the individual projects. In addition. Core C will characterize the physical properties of synthetic standards and prepare biologically derived authentic LM and SPM. These LM will be validated with biologically generated LM (eicosanoids, prostaglandins and leukotrienes) and novel SPM, including resolvins, protectins and maresins, before distributing to each project. By providing a centralized location for LM lipidomics and pathway metabolomics as standardized services, Core C eliminates costly duplication of instruments and personnel within each project. Prioritization of this Core's service and selection of procedures will be carried out via individual meetings with project investigators and the PI at our regular Program Project meetings in order to achieve optimal use of resources and expertise for this Program Project team in a cost-effective and timely fashion.
Core C will serve Projects 1-4 and play a central role in optimizing resources and standardizing methods for identifying, validating and profiling lipid mediators. By providing these centralized services, this core will facilitate interactions and coordinate key experiments for the investigators in this translational Program Project.
| Ma, Kevin C; Schenck, Edward J; Pabon, Maria A et al. (2018) The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness. Am J Respir Crit Care Med 197:300-309 |
| Schenck, Edward J; Oromendia, Clara; Torres, Lisa K et al. (2018) Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. Chest : |
| Schenck, Edward J; Ma, Kevin C; Murthy, Santosh B et al. (2018) Danger Signals in the ICU. Crit Care Med 46:791-798 |
| Ghanta, Sailaja; Kwon, Min-Young; Rosas, Ivan O et al. (2018) Mesenchymal Stromal Cell Therapy: Does the Source Matter? Crit Care Med 46:343-345 |
| Baron, Rebecca M; Kwon, Min-Young; Castano, Ana P et al. (2018) Frontline Science: Targeted expression of a dominant-negative high mobility group A1 transgene improves outcome in sepsis. J Leukoc Biol 104:677-689 |
| Shu, Chang; Huang, He; Xu, Ying et al. (2018) Pressure Overload in Mice With Haploinsufficiency of Striated Preferentially Expressed Gene Leads to Decompensated Heart Failure. Front Physiol 9:863 |
| Harrington, John S; Schenck, Edward J; Oromendia, Clara et al. (2018) Acute respiratory distress syndrome without identifiable risk factors: A secondary analysis of the ARDS network trials. J Crit Care 47:49-54 |
| Siempos, Ilias I; Ma, Kevin C; Imamura, Mitsuru et al. (2018) RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury. JCI Insight 3: |
| Rosas, Ivan O; Goldberg, Hilary J; Collard, Harold R et al. (2018) A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest 153:94-104 |
| Suliman, Hagir B; Kraft, Bryan; Bartz, Raquel et al. (2017) Mitochondrial quality control in alveolar epithelial cells damaged by S. aureus pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 313:L699-L709 |
Showing the most recent 10 out of 85 publications
